Abstract Purpose: Inactivation of Merlin/NF2 is common, occurring in 45-60% of mesotheliomas. Merlin loss leads to hyperactivation of TOR signaling and dysregulation of this pathway drives tumor development and growth. Cytostatic inhibition of TOR with rapamycin in MM cells has limited impact (Lopez-Lago Mol Cell Biol 2009). Rapamycin releases two major negative feedback loops that restrain Akt-TOR signaling, thereby leading to hyperactivation of both Akt and ERK. Effective growth inhibition likely requires dual inhibition of PI3K and mTOR. We therefore sought to assess the activity of the potent and selective dual PI3K/mTOR inhibitor GDC-0980 in MM cells with respect to cell proliferation and hyperactivation of Akt and ERK. Experimental Procedures: NF2 mutant cell lines, VAMT and JMN, and NF2 wild type cell lines, H-Meso and 211-H, were cultured in the presence of increasing concentrations of GDC-0980 for 48 hours and subjected to MTT assay. Values were normalized to untreated samples at day 0. Meso 33 and JMN malignant mesothelioma cell lines were treated with increasing doses of GDC-0980 for 2 hours and subjected to immunoblotting for P-S6, P-4E-BP1, P-Akt (S473), P-ERK, and ERK2. Results: GDC-0980 effectively inhibited proliferation of the NF2 mutant cell lines by 40% but had little or no effect on NF2 wild type cell lines (statistically significant difference at 80 nM with p<0.006). 100 nM GDC-0980 completely suppresses activation of TOR as assessed by phosphorylation of S6 and 4E-BP1 in Meso-33 cells. Higher concentrations were required for these events in JMN cells. However, in both Meso-33 and JMN cells, these effects were not associated with overactivation of Akt or ERK. Conclusions: GDC-0980 is a potent inhibitor of proliferation in MM cells with NF2 mutations and does not cause hyperactivation of Akt and ERK. Along with our ongoing preclinical work with cell lines and xenograft mouse models, the data from a recent phase I clinical trial with an expansion cohort in mesothelioma (NCT00854152) provide a strong rationale for the development of biomarker-driven clinical trials of GDC-0980 and other PI3K/mTOR inhibitors in mesothelioma. This work was supported in part by Genentech. Citation Format: Marjorie G. Zauderer, Kamalika Moulik, Jonathan Cooper, Lee M. Krug, Filippo Giancotti. GDC-0980, a dual PI3K/mTOR inhibitor, selectively inhibits NF2 mutant malignant mesothelioma (MM) cells and inhibits TOR signaling without activating Akt or ERK. [abstract]. In: Proceedings of the AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; Sep 14-17, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(7 Suppl):Abstract nr A34.
Read full abstract